327 related articles for article (PubMed ID: 27482705)
1. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
Kumakech E; Berggren V; Wabinga H; Lillsunde-Larsson G; Helenius G; Kaliff M; Karlsson M; Kirimunda S; Musubika C; Andersson S
PLoS One; 2016; 11(8):e0160099. PubMed ID: 27482705
[TBL] [Abstract][Full Text] [Related]
2. Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study.
Kumakech E; Andersson S; Wabinga H; Musubika C; Kirimunda S; Berggren V
BMC Womens Health; 2017 Jun; 17(1):40. PubMed ID: 28576143
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
4. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
5. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
8. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
9. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
10. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.
Kavanagh K; Pollock KG; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Donaghy M
Br J Cancer; 2014 May; 110(11):2804-11. PubMed ID: 24736582
[TBL] [Abstract][Full Text] [Related]
11. Patterns of prevalent HPV and STI co-infections and associated factors among HIV-negative young Western Cape, South African women: the EVRI trial.
Menezes LJ; Pokharel U; Sudenga SL; Botha MH; Zeier M; Abrahamsen ME; Glashoff RH; Engelbrecht S; Schim van der Loeff MF; van der Laan LE; Kipping S; Taylor D; Giuliano AR
Sex Transm Infect; 2018 Feb; 94(1):55-61. PubMed ID: 28490581
[TBL] [Abstract][Full Text] [Related]
12. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
[TBL] [Abstract][Full Text] [Related]
13. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
[TBL] [Abstract][Full Text] [Related]
14. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
Kudo R; Yamaguchi M; Sekine M; Adachi S; Ueda Y; Miyagi E; Hara M; Hanley SJB; Enomoto T
J Infect Dis; 2019 Jan; 219(3):382-390. PubMed ID: 30299519
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda.
LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M
Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297
[TBL] [Abstract][Full Text] [Related]
16. Correlates of Human Papillomavirus Vaccination and Association with HPV-16 and HPV-18 DNA Detection in Young Women.
Feder MA; Kulasingam SL; Kiviat NB; Mao C; Nelson EJ; Winer RL; Whitham HK; Lin J; Hawes SE
J Womens Health (Larchmt); 2019 Oct; 28(10):1428-1435. PubMed ID: 31264912
[No Abstract] [Full Text] [Related]
17. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
19. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain.
Purriños-Hermida MJ; Santiago-Pérez MI; Treviño M; Dopazo R; Cañizares A; Bonacho I; Trigo M; Fernández ME; Cid A; Gómez D; Ordóñez P; Coira A; Armada MJ; Porto M; Perez S; Malvar-Pintos A;
PLoS One; 2018; 13(8):e0201653. PubMed ID: 30075010
[TBL] [Abstract][Full Text] [Related]
20. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
